Avenue Therapeutics (ATXI) Tops Q3 EPS by 34c
Tweet
Share
E-mailGet Alerts ATXI Hot Sheet
Join SI Premium – FREE
Avenue Therapeutics (NASDAQ: ATXI) reported Q3 EPS of $0.06, $0.34 better than the analyst estimate of ($0.28).
For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
